Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Cook MB, Hurwitz LM, Geczik AM, Butler EN. An up-to-date assessment of US prostate cancer incidence rates by stage and race: a novel approach combining multiple imputation with age and delay adjustment. Eur Urol. 2021;79(1):33–41.

Article  PubMed  Google Scholar 

Cancer Statistics. https://ganjoho.jp/reg_stat/index.html

Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(10):1067–96.

Article  PubMed  CAS  Google Scholar 

D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

Article  PubMed  CAS  Google Scholar 

Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, et al. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation. Int J Clin Oncol. 2019;24(10):1247–55.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, et al. Natural history of surgically treated high-risk prostate cancer. Urol Oncol. 2015;33(4):163.e7-13.

Article  PubMed  Google Scholar 

Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22(1):9–15.

Article  PubMed  CAS  Google Scholar 

Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6(Suppl 10):S13-8.

PubMed  PubMed Central  Google Scholar 

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.

Article  PubMed  Google Scholar 

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.

Article  PubMed  Google Scholar 

Hennrich U, Eder M. [(68)Ga]Ga-PSMA-11: the first FDA-approved (68)Ga-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals (Basel). 2021;14(8):713.

Article  PubMed  CAS  Google Scholar 

Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Wängler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–97.

Article  PubMed  CAS  Google Scholar 

Watabe T, Uemura M, Soeda F, Naka S, Ujike T, Hatano K, et al. High detection rate in [(18)F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients. Ann Nucl Med. 2021;35(4):523–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Harada N, Kimura H, Onoe S, Watanabe H, Matsuoka D, Arimitsu K, et al. Synthesis and biologic evaluation of novel 18F-labeled probes targeting prostate-specific membrane antigen for PET of prostate cancer. J Nucl Med. 2016;57(12):1978–84.

Article  PubMed  CAS  Google Scholar 

Saga T, Nakamoto Y, Ishimori T, Inoue T, Shimizu Y, Kimura H, et al. Initial evaluation of PET/CT with (18) F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients. Cancer Sci. 2019;110(2):742–50.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540–5.

Article  PubMed  CAS  Google Scholar 

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.

Article  PubMed  Google Scholar 

Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, et al. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy. Int J Clin Oncol. 2020;25(4):713–9.

Article  PubMed  CAS  Google Scholar 

Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [(68)Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imaging. 2021;48(9):2925–34.

Article  PubMed  PubMed Central  Google Scholar 

Mena E, Lindenberg ML, Turkbey IB, Shih JH, Harmon SA, Lim I, et al. (18)F-DCFPyL PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. J Nucl Med. 2020;61(6):881–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of (18)F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med. 2019;60(3):362–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Schäfers M, Bögemann M, et al. Diagnostic performance of (18)F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(12):2055–61.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wondergem M, Jansen BHE, van der Zant FM, van der Sluis TM, Knol RJJ, van Kalmthout LWM, et al. Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(9):1911–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, et al. Diagnostic accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT before salvage lymph node dissection for recurrent prostate cancer. Theranostics. 2017;7(6):1770–80.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mütevelizade G, Sezgin C, Gümüşer G, Sayit E. Unexpected metastatic localizations of prostate cancer determined by (68)Ga PSMA PET/CT: series of four cases. Mol Imaging Radionucl Ther. 2022;31(3):223–6.

Article  PubMed  PubMed Central  Google Scholar 

Valle LGM, Rahal A Jr, Falsarella PM, de Andrade JR, Smaletz O, Osawa A, et al. Prostate cancer recurrence in vas deferens - fusion image guide as an important tool in dignosis. Int Braz J Urol. 2018;44(1):192–5.

Article  PubMed  PubMed Central  Google Scholar 

Otani T, Saga T, Ishimori T, Kidera E, Shimizu Y, Aizawa R, et al. Detection efficacy of PET/CT with (18)F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study. Ann Nucl Med. 2022;36(3):302–9.

Article  PubMed  CAS  Google Scholar 

Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, et al. Impact of (68)Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. J Nucl Med. 2020;61(12):1793–9.